US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GRACE THERAPEUTICS INC

3.61

-0.0600-1.63%

Volume:6.28K

Turnover:22.74K

Market Cap:55.86M

PE:-6.81

High:3.63

Open:3.63

Low:3.61

Close:3.67

52wk High:3.94

52wk Low:1.75

Shares:15.47M

Float Shares:9.35M

Volume Ratio:1.40

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5300

EPS(LYR):-0.7916

ROE:-13.15%

ROA:-11.85%

PB:0.89

PE(LYR):-4.56

Loading ...

Overview Company News Filings

Grace Therapeutics Updates Executive Severance and Change-in-Control Compensation Terms

Grace Therapeutics Unveils Data on Novel IV Nimodipine for Subarachnoid Hemorrhage

Grace Therapeutics to Participate in Craig-Hallum Alpha Select Conference

Grace Therapeutics Unveils Data on Novel IV Nimodipine for aSAH Treatment

Grace Therapeutics reports decreased net loss for second quarter 2026

Press Release: Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Grace Therapeutics secures $4M through common warrant exercises

Grace Therapeutics Secures Approximately $4.0 Million Through Common Warrant Exercises Following Acceptance of New Drug Application for Gtx-104 for Formal FDA Review

THOMSON REUTERS

Grace Therapeutics, Inc - FDA Sets Pdufa Target Date of April 23, 2026 for Gtx-104

THOMSON REUTERS

Press Release: Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Grace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial

Grace Therapeutics Pivotal Phase 3 Strive-on Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

THOMSON REUTERS

Grace Therapeutics Inc. Held Annual Stockholders Meeting

Grace Therapeutics Inc. Unveils Presentation on GTx-104 for aSAH Treatment, Highlighting Phase 3 Trial Success and Upcoming NDA Review

Grace Therapeutics, Inc - FDA Sets April 23, 2026 as Pdufa Target Date for Gtx-104

THOMSON REUTERS

Grace Therapeutics Inc. Unveils Presentation on GTx-104's Potential to Revolutionize aSAH Treatment with Intravenous Nimodipine

Grace Therapeutics Q1 EPS $(0.21) Beats $(0.22) Estimate

Grace Therapeutics Reports Increased Net Loss of $3.4 Million in Q1 2026, EPS at $0.21

Grace Therapeutics, Inc expected to post a loss of 22 cents a share - Earnings Preview

Grace Therapeutics Inc. Announces Date for 2025 Annual Meeting of Stockholders

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GRCE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GRCE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRCE\",,,,,undefined,":{"symbol":"GRCE","market":"US","secType":"STK","nameCN":"GRACE THERAPEUTICS INC","latestPrice":3.61,"timestamp":1770821753325,"preClose":3.67,"halted":0,"volume":6284,"delay":0,"changeRate":-0.01634877384196187,"floatShares":9348500,"shares":15474000,"eps":-0.53,"marketStatus":"Trading","change":-0.06,"latestTime":"02-11 10:02:09 EST","open":3.63,"high":3.63,"low":3.61,"amount":22740.6717924,"amplitude":0.00545,"askPrice":3.6,"askSize":22,"bidPrice":3.58,"bidSize":84,"shortable":3,"etf":0,"ttmEps":-0.53,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770843600000},"marketStatusCode":2,"adr":0,"listingDate":1357534800000,"exchange":"NASDAQ","adjPreClose":3.67,"preHourTrading":{"tag":"盘前","latestPrice":3.68,"preClose":3.67,"latestTime":"08:07 EST","volume":350,"amount":1288,"timestamp":1770815225740,"change":0.01,"changeRate":0.002725,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.67,"preClose":3.67,"latestTime":"19:09 EST","volume":36,"amount":134.12,"timestamp":1770768595526,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.400194,"impliedVol":2.4607,"impliedVolPercentile":0.3333},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRCE\",,,,,undefined,":{"symbol":"GRCE","floatShares":9348500,"roa":"-11.85%","roe":"-13.15%","lyrEps":-0.791576,"volumeRatio":1.400194,"shares":15474000,"dividePrice":0,"high":3.63,"amplitude":0.00545,"preClose":3.67,"low":3.61,"week52Low":1.75,"pbRate":"0.89","week52High":3.938,"institutionHeld":0,"latestPrice":3.61,"committee":0.584906,"eps":-0.53,"divideRate":0,"volume":6284,"delay":0,"ttmEps":-0.53,"open":3.63,"prevYearClose":3.46,"prevWeekClose":3.6,"prevMonthClose":3.63,"prevQuarterClose":3.46,"fiveDayClose":3.68,"twentyDayClose":3.54,"sixtyDayClose":3.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GRCE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"GRCE","fiscalQuarterEnding":"2025/09","expectedEps":-0.12,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-0.15},{"market":"US","date":"2025-08-12","symbol":"GRCE","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"","actualEps":-0.21},{"market":"US","date":"2025-06-23","symbol":"GRCE","fiscalQuarterEnding":"2025/03","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1750651200000,"reportTimeType":"pre","actualEps":-0.21},{"market":"US","date":"2025-02-13","symbol":"GRCE","fiscalQuarterEnding":"2024/12","expectedEps":-0.24,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1739422800000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2024-11-13","symbol":"GRCE","fiscalQuarterEnding":"2024/09","expectedEps":-0.33,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.33}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GRCE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GRCE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1746162000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GRCE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GRCE","date":"2026-02-09","current":-6.924528,"percent":0.056782,"low":-7.578711,"twenty":-4.731889,"median":-3.956983,"eighty":-2.764605,"high":-1.653321,"avg":-3.960551,"sd":1.490498,"marketCap":55706493},"quantilePoints":[{"date":"2024-10-31","current":-2.746009,"twenty":-2.84522,"median":-2.808016,"eighty":-2.770812,"marketCap":31433569},{"date":"2024-11-08","current":-2.737151,"twenty":-2.770812,"median":-2.746009,"eighty":-2.701719,"marketCap":31332170},{"date":"2024-11-15","current":-2.891861,"twenty":-2.815988,"median":-2.74158,"eighty":-2.694633,"marketCap":33562939},{"date":"2024-11-22","current":-2.821967,"twenty":-2.824979,"median":-2.746009,"eighty":-2.701719,"marketCap":32751751},{"date":"2024-11-29","current":-2.935545,"twenty":-2.870023,"median":-2.76081,"eighty":-2.701719,"marketCap":34069932},{"date":"2024-12-06","current":-3.791745,"twenty":-2.935545,"median":-2.823849,"eighty":-2.717126,"marketCap":44006996},{"date":"2024-12-13","current":-3.407329,"twenty":-3.407329,"median":-2.865651,"eighty":-2.737151,"marketCap":39545457},{"date":"2024-12-20","current":-3.547117,"twenty":-3.407329,"median":-2.887493,"eighty":-2.746009,"marketCap":41167835},{"date":"2024-12-27","current":-3.232594,"twenty":-3.39335,"median":-2.931176,"eighty":-2.746009,"marketCap":37517485},{"date":"2025-01-03","current":-3.494696,"twenty":-3.396845,"median":-2.953018,"eighty":-2.749647,"marketCap":40559444},{"date":"2025-01-10","current":-3.582064,"twenty":-3.494696,"median":-3.066596,"eighty":-2.755568,"marketCap":41573430},{"date":"2025-01-17","current":-2.935545,"twenty":-3.494696,"median":-3.057859,"eighty":-2.767291,"marketCap":34069932},{"date":"2025-01-24","current":-3.437907,"twenty":-3.492949,"median":-3.145227,"eighty":-2.786004,"marketCap":39900353},{"date":"2025-01-31","current":-2.778283,"twenty":-3.476349,"median":-3.13649,"eighty":-2.78702,"marketCap":32244757},{"date":"2025-02-07","current":-2.918071,"twenty":-3.433539,"median":-3.040386,"eighty":-2.785272,"marketCap":33867135},{"date":"2025-02-14","current":-3.040386,"twenty":-3.416065,"median":-3.038201,"eighty":-2.814977,"marketCap":35286716},{"date":"2025-02-21","current":-2.570989,"twenty":-3.416065,"median":-3.009807,"eighty":-2.777013,"marketCap":34374128},{"date":"2025-02-28","current":-2.29038,"twenty":-3.407329,"median":-2.996702,"eighty":-2.746009,"marketCap":30622380},{"date":"2025-03-07","current":-2.050724,"twenty":-3.407329,"median":-2.952538,"eighty":-2.701719,"marketCap":27418184},{"date":"2025-03-14","current":-1.736745,"twenty":-3.389855,"median":-2.935545,"eighty":-2.613138,"marketCap":23220281},{"date":"2025-03-21","current":-1.941514,"twenty":-3.363645,"median":-2.904966,"eighty":-2.495149,"marketCap":25958044},{"date":"2025-03-28","current":-2.329102,"twenty":-3.337435,"median":-2.883124,"eighty":-2.329102,"marketCap":31140100},{"date":"2025-04-04","current":-2.25728,"twenty":-3.328698,"median":-2.865651,"eighty":-2.3283,"marketCap":30179833},{"date":"2025-04-11","current":-1.99051,"twenty":-3.319961,"median":-2.825732,"eighty":-2.29038,"marketCap":26613125},{"date":"2025-04-17","current":-2.093114,"twenty":-3.278025,"median":-2.81323,"eighty":-2.187348,"marketCap":27984936},{"date":"2025-04-25","current":-2.441966,"twenty":-3.253562,"median":-2.777648,"eighty":-2.187348,"marketCap":32649092},{"date":"2025-05-02","current":-2.780558,"twenty":-3.243078,"median":-2.76081,"eighty":-2.203926,"marketCap":37176067},{"date":"2025-05-09","current":-2.872902,"twenty":-3.234341,"median":-2.778283,"eighty":-2.214186,"marketCap":38410696},{"date":"2025-05-16","current":-2.784047,"twenty":-3.204636,"median":-2.778283,"eighty":-2.249072,"marketCap":37222708},{"date":"2025-05-23","current":-3.04702,"twenty":-3.183669,"median":-2.787433,"eighty":-2.28376,"marketCap":40738659},{"date":"2025-05-30","current":-2.978583,"twenty":-3.159206,"median":-2.802024,"eighty":-2.29493,"marketCap":39823661},{"date":"2025-06-06","current":-3.037068,"twenty":-3.145227,"median":-2.825732,"eighty":-2.310491,"marketCap":40605593},{"date":"2025-06-13","current":-2.996026,"twenty":-3.145227,"median":-2.855425,"eighty":-2.319966,"marketCap":40056869},{"date":"2025-06-20","current":-3.149932,"twenty":-3.145227,"median":-2.867837,"eighty":-2.32375,"marketCap":42114585},{"date":"2025-06-27","current":-4.249161,"twenty":-3.190658,"median":-2.872902,"eighty":-2.328621,"marketCap":40655972},{"date":"2025-07-03","current":-4.523767,"twenty":-3.242086,"median":-2.883124,"eighty":-2.331154,"marketCap":43283399},{"date":"2025-07-11","current":-4.480408,"twenty":-3.326951,"median":-2.892641,"eighty":-2.341415,"marketCap":42868542},{"date":"2025-07-18","current":-4.841731,"twenty":-3.403834,"median":-2.918071,"eighty":-2.351675,"marketCap":46325682},{"date":"2025-07-25","current":-4.624937,"twenty":-3.433539,"median":-2.930636,"eighty":-2.361936,"marketCap":44251398},{"date":"2025-08-01","current":-4.176896,"twenty":-3.536633,"median":-2.935545,"eighty":-2.372196,"marketCap":39964544},{"date":"2025-08-08","current":-4.263614,"twenty":-3.615264,"median":-2.954985,"eighty":-2.392716,"marketCap":40794257},{"date":"2025-08-15","current":-4.12993,"twenty":-3.770777,"median":-2.969531,"eighty":-2.448122,"marketCap":42591970},{"date":"2025-08-22","current":-4.424925,"twenty":-4.171115,"median":-2.986997,"eighty":-2.477228,"marketCap":45634254},{"date":"2025-08-29","current":-4.00925,"twenty":-4.24627,"median":-2.996702,"eighty":-2.502733,"marketCap":41347400},{"date":"2025-09-05","current":-4.103112,"twenty":-4.234708,"median":-3.005439,"eighty":-2.533069,"marketCap":42315399},{"date":"2025-09-12","current":-4.317654,"twenty":-4.278067,"median":-3.026807,"eighty":-2.55483,"marketCap":44527969},{"date":"2025-09-19","current":-4.183566,"twenty":-4.278067,"median":-3.037068,"eighty":-2.570221,"marketCap":43145113},{"date":"2025-09-26","current":-4.12993,"twenty":-4.263614,"median":-3.042574,"eighty":-2.570989,"marketCap":42591970},{"date":"2025-10-03","current":-4.049477,"twenty":-4.249161,"median":-3.047328,"eighty":-2.593742,"marketCap":41762257},{"date":"2025-10-10","current":-4.049477,"twenty":-4.234708,"median":-3.057723,"eighty":-2.595872,"marketCap":41762257},{"date":"2025-10-17","current":-4.304246,"twenty":-4.234708,"median":-3.067849,"eighty":-2.613138,"marketCap":44389684},{"date":"2025-10-24","current":-4.223792,"twenty":-4.234708,"median":-3.088369,"eighty":-2.616494,"marketCap":43559970},{"date":"2025-10-31","current":-4.277428,"twenty":-4.249161,"median":-3.127753,"eighty":-2.626653,"marketCap":44113112},{"date":"2025-11-07","current":-4.472902,"twenty":-4.277428,"median":-3.147579,"eighty":-2.626653,"marketCap":46129039},{"date":"2025-11-14","current":-4.561183,"twenty":-4.285293,"median":-3.197647,"eighty":-2.667694,"marketCap":47039480},{"date":"2025-11-21","current":-5.673105,"twenty":-4.29252,"median":-3.241803,"eighty":-2.677955,"marketCap":44363684},{"date":"2025-11-28","current":-5.745374,"twenty":-4.304791,"median":-3.258804,"eighty":-2.688958,"marketCap":44928827},{"date":"2025-12-05","current":-5.926046,"twenty":-4.321299,"median":-3.328698,"eighty":-2.692631,"marketCap":46341683},{"date":"2025-12-12","current":-6.070584,"twenty":-4.338036,"median":-3.37675,"eighty":-2.699947,"marketCap":47471968},{"date":"2025-12-19","current":-6.628899,"twenty":-4.37129,"median":-3.407329,"eighty":-2.701719,"marketCap":51837987},{"date":"2025-12-26","current":-6.668474,"twenty":-4.381422,"median":-3.416065,"eighty":-2.710963,"marketCap":52147467},{"date":"2026-01-02","current":-6.846564,"twenty":-4.398844,"median":-3.485959,"eighty":-2.725136,"marketCap":53540129},{"date":"2026-01-09","current":-7.519348,"twenty":-4.414931,"median":-3.520906,"eighty":-2.740694,"marketCap":58801298},{"date":"2026-01-16","current":-7.202743,"twenty":-4.455514,"median":-3.582064,"eighty":-2.746009,"marketCap":56325454},{"date":"2026-01-23","current":-7.519348,"twenty":-4.480408,"median":-3.617011,"eighty":-2.747222,"marketCap":58801298},{"date":"2026-01-30","current":-6.945503,"twenty":-4.55824,"median":-3.673799,"eighty":-2.75382,"marketCap":54313831},{"date":"2026-02-06","current":-6.886139,"twenty":-4.648062,"median":-3.931533,"eighty":-2.762708,"marketCap":53849610},{"date":"2026-02-09","current":-7.123592,"twenty":-4.731889,"median":-3.956983,"eighty":-2.764605,"marketCap":55706493}],"updateTime":1770785174420},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GRCE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603529236","title":"Grace Therapeutics Updates Executive Severance and Change-in-Control Compensation Terms","url":"https://stock-news.laohu8.com/highlight/detail?id=2603529236","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603529236?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:01","pubTimestamp":1768255295,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Inc. has amended its compensation agreements for key executives, including CEO Prashant Kohli and Principal Financial Officer Robert J. DelAversano. Under the new terms, if an executive is terminated without cause outside of a change in control, they will receive accrued salary and benefits, as well as a continuation of base salary and COBRA premium payments for six months, or twelve months for the CEO. In the event of a termination without cause or resignation for good reason within twelve months following a change in control, executives are entitled to a lump-sum payment equal to six months of base salary and target bonus, or eighteen months for the CEO, along with corresponding COBRA premium coverage. Additionally, all unvested equity awards will fully vest in connection with such terminations related to a change in control.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL8tNp59:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2588671532","title":"Grace Therapeutics Unveils Data on Novel IV Nimodipine for Subarachnoid Hemorrhage","url":"https://stock-news.laohu8.com/highlight/detail?id=2588671532","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588671532?lang=en_us&edition=fundamental","pubTime":"2025-12-01 05:55","pubTimestamp":1764539734,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Inc. has provided an overview of its lead product candidate, GTx-104, a novel intravenous formulation of nimodipine designed for the treatment of aneurysmal subarachnoid hemorrhage . The company highlights unmet needs with the current standard of care, oral nimodipine, and positions GTx-104 as a potential alternative that may address oral delivery challenges. The pivotal Phase 3 STRIVE-ON safety trial met its primary endpoint, demonstrating clinical evidence of benefit compared to oral nimodipine. GTx-104 has received Orphan Drug Status, granting seven years of market exclusivity, and is supported by additional intellectual property protections. The New Drug Application  for GTx-104 was filed in June 2025 and accepted for review in August 2025, with a target Prescription Drug User Fee Act  date of April 23, 2026. You can access the full presentation through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251130:nNDL7nLpVP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2584962557","title":"Grace Therapeutics to Participate in Craig-Hallum Alpha Select Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584962557","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584962557?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:03","pubTimestamp":1763384583,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Inc. will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, in New York. The company will present its clinical-stage, novel injectable formulation of nimodipine, GTx-104, which is being developed for IV infusion to address unmet medical needs in aneurysmal subarachnoid hemorrhage patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL3dM8G9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2583551969","title":"Grace Therapeutics Unveils Data on Novel IV Nimodipine for aSAH Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2583551969","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583551969?lang=en_us&edition=fundamental","pubTime":"2025-11-14 04:28","pubTimestamp":1763065701,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Inc. has provided an update on GTx-104, its novel intravenous formulation of nimodipine, developed for the treatment of aneurysmal subarachnoid hemorrhage . GTx-104 is designed to address challenges associated with the oral administration of nimodipine, the current standard of care, by offering an intravenous option that may improve drug delivery and patient outcomes. The pivotal Phase 3 STRIVE-ON safety trial met its primary endpoint and demonstrated clinical evidence of benefit compared to the oral formulation. GTx-104 has been granted Orphan Drug Status, providing seven years of market exclusivity and additional intellectual property protection. The company filed a New Drug Application  for GTx-104 in June 2025, which was accepted for review in August 2025. The target Prescription Drug User Fee Act  date is set for April 23, 2026. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLb5hHxB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2583598853","title":"Grace Therapeutics reports decreased net loss for second quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598853","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598853?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:03","pubTimestamp":1763039016,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Inc. reported a net loss of $0.9 million for the three months ended September 30, 2025, a decrease of $2.5 million from a net loss of $3.4 million for the same period in 2024. Research and development expenses were $0.6 million, down from $3.0 million, mainly due to the completion of the GTx-104 pivotal Phase 3 STRIVE-ON safety trial. General and administrative expenses increased slightly to $2.0 million from $1.9 million, primarily due to pre-commercial planning costs for GTx-104. Cash and cash equivalents as of September 30, 2025, were $16.9 million, a decrease of $5.2 million from March 31, 2025. In October 2025, the company received $4.0 million from exercises of common warrants. Key business developments included FDA acceptance for review of the New Drug Application for GTx-104, with a PDUFA target date set for April 23, 2026, and the presentation of Phase 3 STRIVE-ON trial data.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL2kzYDk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2583022560","title":"Press Release: Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583022560","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583022560?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:00","pubTimestamp":1763038800,"startTime":"0","endTime":"0","summary":"Announced U.S. Food and Drug Administration  Acceptance for Review. FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage . Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Neurocritical Care Annual Meeting. Granted Sixth U.S. Patent Covering IV Dosing Regimen for GTx-104. PRINCETON, N.J., Nov. 13, 2025  -- Grace Therapeutics, Inc.  , a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the quarter ended September 30, 2025.-- On August 22, 2025, the FDA accepted the Company's NDA for GTx-104 for","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","IE00BD6J9T35.USD","IE00BZ199S13.USD","BK4082","LENZ","BK4007","ICU","BK4512","BK4539","LU1861215975.USD","LU2360107325.USD","BK4139","LU0124384867.USD","LU1861219969.SGD","LU2357305700.SGD","IE00BFMHRM44.USD","LU1854103824.USD","RDI","LU1720051017.SGD","BK4605","LU1978683503.SGD","GRCE","BK4108","LU2298322129.HKD","BK4588","LU0724618433.USD","LU1720051108.HKD","LU1861214812.USD","LU0348723411.USD","LU1861220033.SGD","LU1854104046.USD","LU1548497426.USD","ON","BK4585"],"gpt_icon":0},{"id":"2577710301","title":"Grace Therapeutics secures $4M through common warrant exercises","url":"https://stock-news.laohu8.com/highlight/detail?id=2577710301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577710301?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:15","pubTimestamp":1761221745,"startTime":"0","endTime":"0","summary":"Grace Therapeutics (GRCE) has secured approximately $4.0 million in additional funding through exercises of common warrants that were previously is...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grace-therapeutics-secures-4m-through-common-warrant-exercises-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grace-therapeutics-secures-4m-through-common-warrant-exercises-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRCE","LENZ","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2577601309","title":"Grace Therapeutics Secures Approximately $4.0 Million Through Common Warrant Exercises Following Acceptance of New Drug Application for Gtx-104 for Formal FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2577601309","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577601309?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:00","pubTimestamp":1761220805,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA7LYVCY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2577309240","title":"Grace Therapeutics, Inc - FDA Sets Pdufa Target Date of April 23, 2026 for Gtx-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2577309240","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577309240?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:00","pubTimestamp":1761220805,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA7LYVCY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2577309234","title":"Press Release: Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2577309234","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577309234?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:00","pubTimestamp":1761220800,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Oct. 23, 2025  -- Grace Therapeutics, Inc.  , a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage  patients, today announced it has secured approximately $4.0 million in additional funding through exercises of common warrants that were previously issued in a private placement that the Company closed in September 2023. The Company issued 1,345,464 new shares of common stock at an exercise price of $3.003 per share. The remaining 1,190,927 common warrants issued in the 2023 private placement have expired as the 60th day after the U.S. Food and Drug Administration's  acceptance for review of the Company's New Drug Application for GTx-104 has passed.Grace Therapeutics, Inc.  is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics' novel drug deli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","GRCE","BK4539","BK4007"],"gpt_icon":0},{"id":"2569784748","title":"Grace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2569784748","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569784748?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:21","pubTimestamp":1758543665,"startTime":"0","endTime":"0","summary":"Grace Therapeutics (GRCE) announced that results from its Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH were presented at the 2025 Neur...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grace-therapeutics-announces-presentation-of-phase-3-strive-on-safety-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grace-therapeutics-announces-presentation-of-phase-3-strive-on-safety-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1978683503.SGD","BK4139","BK4539","ASST","LU1861219969.SGD","LU1548497426.USD","LU0124384867.USD","LU1861215975.USD","LU1861214812.USD","LU1854103824.USD","GRCE","LU1720051108.HKD","BK4585","BK4588","LU2298322129.HKD","BK4009","BK4007","LU2357305700.SGD","BK4605","ON","LU1854104046.USD","LU1720051017.SGD","LENZ","BK4141","IE00BZ199S13.USD","LU0724618433.USD","LU0348723411.USD","LU1861220033.SGD","BK4512","LU2360107325.USD","IE00BD6J9T35.USD"],"gpt_icon":0},{"id":"2569812647","title":"Grace Therapeutics Pivotal Phase 3 Strive-on Safety Trial Presented at 2025 Neurocritical Care Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2569812647","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569812647?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:00","pubTimestamp":1758542401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nTUA20L6R3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2567123901","title":"Grace Therapeutics Inc. Held Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2567123901","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567123901?lang=en_us&edition=fundamental","pubTime":"2025-09-13 04:13","pubTimestamp":1757708017,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Inc. held its Annual Meeting of Stockholders on September 12, 2025. During the meeting, several proposals were voted on. The election of directors resulted in the appointment of Vimal Kavuru, A. Brian Davis, Prashant Kohli, S. George Kottayil, and Edward Neugeboren. The stockholders approved the advisory vote on executive officer compensation. Additionally, the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026, was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDLbSr7dh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2562498937","title":"Grace Therapeutics Inc. Unveils Presentation on GTx-104 for aSAH Treatment, Highlighting Phase 3 Trial Success and Upcoming NDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2562498937","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562498937?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:35","pubTimestamp":1756298137,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Inc. Unveils Presentation on GTx-104 for aSAH Treatment, Highlighting Phase 3 Trial Success and Upcoming NDA Review. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief on August 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL6J9NRS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2562745400","title":"Grace Therapeutics, Inc - FDA Sets April 23, 2026 as Pdufa Target Date for Gtx-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2562745400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562745400?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:00","pubTimestamp":1756296001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nTUABFZXDC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2559861709","title":"Grace Therapeutics Inc. Unveils Presentation on GTx-104's Potential to Revolutionize aSAH Treatment with Intravenous Nimodipine","url":"https://stock-news.laohu8.com/highlight/detail?id=2559861709","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559861709?lang=en_us&edition=fundamental","pubTime":"2025-08-14 03:14","pubTimestamp":1755112471,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Inc. Unveils Presentation on GTx-104's Potential to Revolutionize aSAH Treatment with Intravenous Nimodipine. Grace Therapeutics Inc. has released a corporate presentation detailing the development of GTx-104, a novel intravenous form of nimodipine. This treatment is positioned to address significant unmet needs in the management of aneurysmal Subarachnoid Hemorrhage  by potentially displacing the current oral standard of care. The pivotal Phase 3 STRIVE-ON safety trial for GTx-104 has successfully met its primary endpoint, showing clinical benefits over oral nimodipine. With Orphan Drug Status, the drug is set to receive seven-year market exclusivity, complemented by multi-layered intellectual property protection. A New Drug Application was submitted in June 2025. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL85xpR2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2558644668","title":"Grace Therapeutics Q1 EPS $(0.21) Beats $(0.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2558644668","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558644668?lang=en_us&edition=fundamental","pubTime":"2025-08-12 20:07","pubTimestamp":1755000462,"startTime":"0","endTime":"0","summary":"Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.22) by 4.55 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47055998/grace-therapeutics-q1-eps-0-21-beats-0-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","GRCE"],"gpt_icon":0},{"id":"2558644013","title":"Grace Therapeutics Reports Increased Net Loss of $3.4 Million in Q1 2026, EPS at $0.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2558644013","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558644013?lang=en_us&edition=fundamental","pubTime":"2025-08-12 20:04","pubTimestamp":1755000241,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL1CPQ0D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE"],"gpt_icon":0},{"id":"2557593243","title":"Grace Therapeutics, Inc  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2557593243","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557593243?lang=en_us&edition=fundamental","pubTime":"2025-08-08 03:02","pubTimestamp":1754593324,"startTime":"0","endTime":"0","summary":"Grace Therapeutics, Inc  expected to post a loss of22cents a share - Earnings Preview Grace Therapeutics, Inc GRCE.OQ GRCE.O is expected to  show no change in quarterly revenue when it reports  result","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nL8N3TZ2ZY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE"],"gpt_icon":0},{"id":"2554753267","title":"Grace Therapeutics Inc. Announces Date for 2025 Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2554753267","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554753267?lang=en_us&edition=fundamental","pubTime":"2025-07-28 19:01","pubTimestamp":1753700517,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Inc. has scheduled its 2025 Annual Meeting of Stockholders to be held virtually on September 12, 2025. During this meeting, shareholders will convene to discuss and vote on various proposals pertinent to the company's future direction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL2mqW4J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}